CD19 and acute lymphoblastic leukemia: For example, a trispecific antibody (CD19×CD22×CD3) restored cytotoxicity against CD19^-/low clones in vitro and prevented emergence of antigen-negative subpopulations in preclinical B-ALL models (225).